New approaches for improving outcomes in breast cancer in Europe

Breast

Volumn 24, Issue 4, 2015, Pages 321-330

  Di Leo, Angelo ^a   Curigliano, Giuseppe ^b   Diéras, Véronique ^c   Malorni, Luca ^a   Sotiriou, Christos ^d   Swanton, Charles ^e   Thompson, Alastair ^f   Tutt, Andrew ^g   Piccart, Martine ^d  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c INSTITUT CURIE   (France)

^d JULES BORDET INSTITUTE   (Belgium)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarker; Breast cancer; Classification; Pathogenesis; Resistance; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; NEW DRUG; TUMOR MARKER; PHARMACOLOGICAL BIOMARKER;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; DRUG DEVELOPMENT; DRUG TARGETING; EUROPE; HEALTH CARE NEED; HUMAN; METASTASIS; MOLECULAR PATHOLOGY; MULTIDRUG RESISTANCE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; SYSTEMIC THERAPY; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; BREAST NEOPLASMS; CLASSIFICATION; DRUG RESISTANCE; FEMALE; MOLECULARLY TARGETED THERAPY; MORTALITY;

ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EUROPE; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84930753890     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2015.03.001     Document Type: Review

References (101)

1. World Health Organization The global burden of disease: 2004 update 2008, WHO, Available at:. http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html.
2. Luengo-Fernandez R., Leal J., Sullivan R. Economic burden of malignant neoplasms in the European Union 2012, Presented at ESMO, Vienna, Austria, 28 September-2 October 2012. Abstr. 1415PD_PR.
3. Holleczek B., Arndt V., Stegmaier C., Brenner H. Trends in breast cancer survival in Germany from 1976 to 2008 - a period analysis by age and stage. Cancer Epidemiol 2011, 35:399-406.
4. García Rodríguez J., García Colmenero C., Clèries Soler R., Oleaga Sánchez I. Five years survival of women diagnosed with breast cancer during the period 1997-1999 in Toledo-Centro and Mancha Area, Spain. Rev Esp Salud Publica 2010, 84:843-850. [Article in Spanish].
5. Chia S.K., Speers C.H., D'yachova Y., Kang A., Malfair-Taylor S., Barnett J., et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2006, 110:973-979.
6. Gennari A., Conte P., Rosso R., Orlandini C., Bruzzi P. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005, 104:1742-1750.
7. Dafni U., Grimani I., Xyrafas A., Eleftheraki A.G., Fountzilas G. Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat 2010, 119:621-631.
8. Allemani C., Sant M., Weir H.K., Richardson L.C., Baili P., Storm H., et al. Breast cancer survival in the US and Europe: a CONCORD high-resolution study. Int J Cancer 2013, 132:1170-1181.
9. National Comprehensive Cancer Network Clinical practice guidelines in oncology. Breast cancer 2013, Version 3, Available at:. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
10. Fritz P., Klenk S., Goletz S., Gerteis A., Simon W., Brinkmann F., et al. Clinical impacts of histological subtyping primary breast cancer. Anticancer Res 2010, 30:5137-5144.
11. Edge S.B., Byrd D.R., Compton C.C., Fritz A.G., Greene F.L., Trotti A. AJCC cancer staging manual 2010, Springer, New York. 7th ed.
12. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352.
13. Phipps A.I., Chlebowski R.T., Prentice R., McTiernan A., Stefanick M.L., Wactawski-Wende J., et al. Bodysize, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev 2011, 20:454-1987.
14. Aebi S., Sun Z., Braun D., Price K.N., Castiglione-Gertsch M., Rabaglio M., et al. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Ann Oncol 2011, 22:1981-1987.
15. Albain K.S., Barlow W.E., Shak S., Hortogagyi G.N., Livingston R.B., Yeh I.T., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010, 11:55-65.
16. Wo J.Y., Taghian A.G., Nguyen P.L., Raad R.A., Sreedhara M., Bellon J.R., et al. The association between biological subtype and isolated regional nodal failure after breast-conserving therapy. Int J Radiat Oncol Biol Phys 2010, 77:188-196.
17. Onitilo A.A., Engel J.M., Greenlee R.T., Mukesh B.N. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009, 7:4-13.
18. Becker M., Sommer A., Krätzschmar J.R., Seidel H., Pohlenz H.D., Fichtner I. Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther 2005, 4:151-168.
19. Lapuk A., Marr H., Jakkula L., Pedro H., Bhattacharya S., Purdom E., et al. Exon-level microarray analyses identify alternative splicing programs in breast cancer. Mol Cancer Res 2010, 8:961-974.
20. Bibikova M., Yeakley J.M., Chudin E., Chen J., Wickham E., Wang-Rodriguez J., et al. Gene expression profiles in formalin-fixed, paraffin-embedded tissues obtained with a novel assay for microarray analysis. Clin Chem 2004, 50:2384-2386.
21. Exner R., Bago-Horvath Z., Bartsch R., Mittiboeck M., Retel V.P., Fitzal F., et al. The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER(+), HER2(-) early breast cancer. Br J Cancer 2014, 111:837-842.
22. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., et al. Amultigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. NEngl J Med 2004, 351:2817-2826.
23. Parker J.S., Mullins M., Cheang M.C.U., Leung S., Voduc D., Vickery T., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. JClin Oncol 2009, 27:1160-1167.
24. Cheang M.C., Chia S.K., Voduc D., Gao D., Leung S., Snider J., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. JNatl Cancer Inst 2009, 101:736-750.
25. Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thurlimann B., Senn H.J., et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22:1736-1747.
26. Walker R.A. Immunohistochemical markers as predictive tools for breast cancer. JClin Pathol 2008, 61:689-696.
27. Hammond M.E., Hayes D.F., Wolff A.C., Mangu P.B., Temin S. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. JOncol Pract 2010, 6:195-197.
28. Wolff A.C., Hammond M.E., Hicks D.G., Dowsett M., McShane L.M., Allison K.H., et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. JClin Oncol 2013, 31:3997-4013.
29. Dowsett M., Nielsen T.O., A'Hern R., Bartlett J., Coombes R.C., Cuzick J., et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. JNatl Cancer Inst 2011, 103:1656-1664.
30. Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., Piccart-Gebhart M., Thurlimann B., et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2012. Ann Oncol 2013, 24:2206-2223.
31. Cardoso F., Costa A., Norton L., Cameron D., Cufer T., Fallowfield L., et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012, 21:242-252.
32. Aebi S., Davidson T., Gruber G., Cardoso F. ESMO Guidelines Working Group. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011, 22(Suppl.6):vi12-24.
33. Bauerschlag D.O., Maass N., Schem C. Standard of care and controversies in the adjuvant endocrine treatment of hormone-responsive early breast cancer. Breast Care 2014, 9:283-286.
34. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. Arandomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. NEngl J Med 2003, 349:1793-1802.
35. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Livingston R.B., et al. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol 2013, 24:355-361.
36. Ingle J.N. Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors. Breast 2013, 22(Suppl.1):S19. (Abstr. SP10.05).
37. Amir E., Seruga B., Niraula S., Carlsson L., Ocana A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. JNatl Cancer Inst 2011, 103:1299-1309.
38. Lin N.U., Thomssen C., Cardoso F., Cameron D., Cufer T., Fallowfield L., et al. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)eMBC Task Force: surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast 2013, 22:203-210.
39. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov 2004, 3:711-715.
40. Hadad S., Iwamoto T., Jordan L., Purdie C., Bray S., Baker L., et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 2011, 128:783-794.
41. Lemieux J., Goodwin P.J., Bordeleau L.J., Lauzier S., Théberge V. Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009). JNatl Cancer Inst 2011, 103:178-231.
42. Chang H.R., Slamon D., Gornbein J.A., Chung D. Preferential pathologic complete response (pCR) by triple-negative (-) breast cancer to neoadjuvant docetaxel (T) and carboplatin (C). JClin Oncol 2008, 26(Suppl.). Abstr. 604.
43. Chollet P., Amat S., Cure H., de Latour M., Le Bouedec G., Mouret-Reynier M.A., et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002, 86:1041-1046.
44. Food and Drug Administration Guidance for industry. Pathologic complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval May 2012, Draft Guidance, Available at:. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM305501.pdf.
45. European Medicines Agency Concept paper on the need to revise condition-specific guidance, Appendix 4 to the guideline on the evaluation of anticancer medicinal products in man July 2013, Available at:. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/07/WC500146992.pdf.
46. Rodenhiser D.I., Andrews J.D., Vandenberg T.A., Chambers A.F. Gene signatures of breast cancer progression and metastasis. Breast Cancer Res 2011, 13:201.
47. Breast International Group, 2012, Available at: . http://www.breastinternationalgroup.org/.
48. Blanco M.A., Kang Y. Signaling pathways in breast cancer metastasis - novel insights from functional genomics. Breast Cancer Res 2011, 13:206.
49. Chou J., Lin J.H., Brenot A., Kim J.W., Provot S., Werb Z., et al. GATA3 suppresses metastases and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol 2013, 15:210-213.
50. Goodarzi H., Zhang S., Buss C., Fish L., Tavazoie S., Tavazoie S.F., et al. Metastasis-suppressor transcript destabilization through TARBP2 binding of mRNA hairpins. Nature 2014, 513:256-260.
51. Oskarsson T., Acharyya S., Zhang X.H., Vanharanta S., Tavazoie S.F., Morris P.G., et al. Breast cancer cells produce tenascin c as a metastatic niche component to colonize the lungs. Nat Med 2011, 17:867-874.
52. Lorusso G., Ruegg C. New insights into the mechanisms of organ-specific breast cancer metastasis. Semin Cancer Biol 2012, 22:226-333.
53. Budd G.T., Cristofanilli M., Ellis M.J., Stopeck A., Borden E., Miller M.C., et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006, 12:6403-6409.
54. Casciano I., Di Vinci A., Banelli B., Brigati C., Forlani A., Allemanni G., et al. Circulating tumor nucleic acids: perspective in breast cancer. Breast Care (Basel) 2010, 5:75-80.
55. Mikulová V., Cabiňaková M., Janatková I., Mestek O., Zima T., Tesarova P., et al. Detection of circulating tumor cells during follow-up of patients with early breast cancer: clinical utility for monitoring of therapy efficacy. Scand J Clin Lav Invest 2014, 74:132-142.
56. Hartkopf A.D., Wagner P., Wallwiener D., Fehm T., Rothmund R. Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer. Anticancer Res 2011, 31:979e84.
57. Pierga J.Y., Hajage D., Bachelot T., Delaloge S., Brain E., Campone M., et al. High independent prognostic and predictive value of circulating tumor cellscompared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2012, 23:618e24.
58. Shaw J.A., Page K., Blighe K., Hava N., Guttery D., Ward B., et al. Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res 2012, 22:220-231.
59. Perkins G., Yap T., Pope L., Cassidy A.M., Dukes J.P., Riisnaes R., et al. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancer. PLoS One 2012, 7:e47020.
60. Swanton C., Burrell R.A., Futreal P.A. Breast cancer genome heterogeneity: a challenge to personalised medicine?. Breast Cancer Res 2011, 13:104.
61. Vignot S., Besse B., Andre F., Spano J.P., Soria J.C. Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers. Crit Rev Oncol Hematol 2012, 84:301-313.
62. Aurilio G., Monfardini L., Rizzo S., Sciandivasci A., Preda L., Bagnardi V., et al. Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. Acta Oncol 2013, 52:1649-1656.
63. Fisher R., Pusztai L., Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 2013, 108:479-485.
64. Pivot X., Asmar L., Buzdar A.U., Valero V., Hortobagyi G. Aunified definition of clinical anthracycline resistance breast cancer. Br J Cancer 2000, 82:529-534.
65. Pohlmann P.R., Mayer I.A., Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009, 15:7479-7491.
66. Dees E.C., Carey L.A. Improving endocrine therapy for breast cancer: it's not that simple. JClin Oncol 2013, 31:171-173.
67. Schiff R., Massarweh S., Shou J., Osbourne C.K. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003, 9:447S-454S.
68. Yap T.A., Gerlinger M., Futreal P.A., Pusztai L., Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012, 4:127.
69. Lupien M., Meyer C.A., Bailey S.T., Eeckhoute J., Cook J., Westerling T., et al. Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. Genes Dev 2010, 24:2219-2227.
70. Miller T.W., Balko J.M., Arteaga C.L. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. JClin Oncol 2011, 29:4452-4461.
71. Miller T.W., Balko J.M., Fox E.M., Ghazoui Z., Dunbier A., Anderson H., et al. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 2011, 1:338-351.
72. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. NEngl J Med 2012, 366:520-529.
73. Finn R.S., Dering J., Conklin D., Kalous O., Cohen D.J., Desai A.J., et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines invitro. Breast Cancer Res 2009, 11:R77.
74. Finn R.S., Crown J.P., Boer K., Lang I., Parikh R.J., Breazna A., et al. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (BC). Ann Oncol 2012, 23(Suppl.2):ii43-ii45.
75. Johnston S.R., Lu B., Scott G.K., Kushner P.J., Smith I.E., Dowsett M., et al. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 1999, 5:251-256.
76. Schiff R., Reddy P., Ahotupa M., Coronado-Heinsohn E., Grim M., Hilsenbeck S.G., et al. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors invivo. JNatl Cancer Inst 2000, 92:1926-1934.
77. Sabnis G., Goloubeva O., Gilani R., Macedo L., Brodie A. Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment. Mol Cancer Ther 2010, 9:46-56.
78. Santarpia L., Qi Y., Stemke-Hale K., Wang B., Young E.F., Booser D.J., et al. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat 2012, 134:333-343.
79. Turner N., Pearson A., Sharpe R., Lambros M., Geyer F., Lopez-Garcia M.A., et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010, 70:2085-2094.
80. Raghav K.P., Wang W., Liu S., Chavez-MacGregor M., Meng X., Hotobagyi G.N., et al. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 2012, 18:2269-2277.
81. Ellisen L.W. PARP inhibitors in cancer therapy: promise, progress, and puzzles. Cancer Cell 2011, 19:165-167.
82. Tutt A., Robson M., Garber J.E., Domchek S.M., Audeh M.W., Weitzel J.N., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244.
83. Reyal F., Guyader C., Decraene C., Lucchesi C., Auger N., Assayag F., et al. Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res 2012, 14:R11.
84. Landis M., Lehmann B., Pietenpol J., Chang J.C. Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Res 2013, 15:201.
85. Wolf M., Swaisland H., Averbuch S. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. Clin Cancer Res 2004, 10:4607-4613.
86. Sarmiento R., Gasparini G. Antiangiogenic metronomic chemotherapy. Onkologie 2008, 31:161-162.
87. Rao B., Lain S., Thompson A.M. p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy. Br J Cancer 2013, 109:2954-2958.
88. Tarhini A.A., Iqbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther 2010, 3:15-25.
89. Hirano F., Kaneko K., Tamura H., Dong H., Wang S., Ichikawa M., et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005, 65:1089-1096.
90. Ellis G.K., Bone H.G., Chlebowski R., Paul D., Spadafora S., Smith J., et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. JClin Oncol 2008, 26:4875-4882.
91. Zelek L., Yovine A., Brain E., Turpin F., Taamma A., Riofrio M., et al. Aphase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 2006, 94:1610-1614.
92. Mom C.H., Verweij J., Oldenhuis C.N., Gietema J.A., Fox N.L., Miceli R., et al. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res 2009, 15:5584-5590.
93. Herbst R.S., Eckhardt S.G., Kurzrock R., Ebbinghaus S., O'Dwyer P.J., Gordon M.S., et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. JClin Oncol 2010, 28:2839-2846.
94. DeClerck Y.A. Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer. Eur J Cancer 2000, 36:1258-1268.
95. Jezierska A., Motyl T. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit 2009, 15:RA32-RA40.
96. Fingleton B. Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects. Expert Opin Ther Targets 2003, 7:385-397.
97. Alexe G., Dalgin G.S., Scanfeld D., Tamayo P., Mesirov J.P., DeLisi C., et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res 2007, 67:10669-10676.
98. Correa I., Plunkett T. Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition. Breast Cancer Res 2001, 3:399-403.
99. Loi S., Sirtaine N., Piette F., Salgado R., Viale G., Van Eenoo F., et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. JClin Oncol 2013, 31:860-867.
100. Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. JClin Invest 2011, 121:2750-2767.
101. Masuda H., Baggerly K.A., Wang Y., Zhang Y., Gonzalez-Angulo A.M., Meric-Bernstam F., et al. Differential response to neoadjuvant chemotherapy among 7 triple-negativebreast cancer molecular subtypes. Clin Cancer Res 2013, 19:5533-5540.